Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3

Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date.

24/7 Wall Street • 15 hours ago

Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS

Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • 11 hours ago

Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development

SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.

Business Wire • 10 hours ago

Are Your Dividends Safe? 4 Yields That Are High for the Wrong Reason

Some of the fattest dividend yields on the market right now come from stocks that have already cut their payouts once, and three more may be quietly building toward the same moment.

24/7 Wall Street • 11 hours ago

Looking for income? These dividend stocks have high yields that seem well supported.

Ford, Pfizer and Verizon are among 11 stocks that passed a screen of the S&P 500 for high dividend yields that are expected to be well covered by the companies' free cash flow.

Market Watch • 9 hours ago

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Zacks Investment Research • 7 hours ago

Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.

Zacks Investment Research • Oct 28, 2026

Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.

Zacks Investment Research • Oct 28, 2026

Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients

Pfizer Inc. (NYSE:PFE) on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy.

Benzinga • Oct 27, 2026

Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2026